The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Rheumatology Year in Review 2021

Clinical Rheumatology Year in Review 2021

November 22, 2021 • By Samantha C. Shapiro, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Costenbader discussed the ARTIC REWIND trial, which examined decreased therapeutic dosages in RA patients in remission. The study compared RA patients in remission kept on stable doses of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with those whose doses were cut in half.5 Patients whose csDMARDs were tapered to half dose experienced a statistically significant increased number of flares during the 12 months of the study.

You Might Also Like
  • Clinical Rheumatology Year in Review—2022
  • Pediatric Rheumatology Year in Review, 2021: Basic Science
  • A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
Also By This Author
  • Advocacy Leadership Conference: Reflections from an Accidental Rheumatology Advocate

“Results from this study and others like it have been reflected in the new 2021 ACR guideline for the management of RA, which conditionally recommend continuing the same dose of csDMARD in RA patients in remission,” Dr. Costenbader noted.6

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, she acknowledged that these data could be interpreted differently because 75% of patients were able to tolerate dose reduction. “We can now tell patients interested in tapering that their risk of flare in the upcoming year is about 25% based on the data, but we don’t know exactly their personalized risk,” said Dr. Costenbader. “Shared decision making again remains the name of the game.”

TICOSPA Trial

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Costenbader turned to the TICOSPA trial, which examined the efficacy of a treat-to-target and tight-control approach in managing axial spondyloarthritis (axSpA).7 Such an approach requires rapid assessment of a patient’s response, with treatment intensification until a prespecified target is reached. Such an approach has been demonstrated effective in RA. This was the first trial to directly test this approach in axial spondyloarthritis against usual care.  

The trial failed to meet its primary outcome of a 30% improvement in the Axial SpondyloArthritis International Society-Health Index (ASAS-HI; a tool to assess disability and functioning in spondyloarthritis). However, it did meet several secondary outcomes, adding 0.4 quality adjusted life years (QALY). (Note: QALY is a measure of disease burden: One QALY denotes one year of perfect health.)

The treat-to-target and tight-control treatment strategy also reduced overall healthcare spending. Of note, the usual care group was still treated at an expert academic center, and results might have been more striking in a general population.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Stepped Exercise for Knee Osteoarthritis

Dr. Costenbader also highlighted a trial of a stepped-exercise program for patients with knee osteoarthritis.8 U.S. Department of Veterans Affairs (VA) patients were randomized to receive a stepped-exercise program or basic arthritis education.

The intervention group received internet-based exercise instruction for three months. If patients in the intervention group did not adequately improve, they were stepped up to biweekly phone-based exercise coaching sessions and then, ultimately, to in-person physical therapy, if needed.

Pages: 1 2 3 4 5 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Osteoarthritis, Rheumatoid Arthritis, Vasculitis Tagged With: ACR Convergence 2021, ACR Convergence 2021 – RA, Clinical, Clinical research, JAK inhibitors, jakinibs, Janus Kinase Inhibitors, Knee Osteoarthritis (OA), stepped exercise

You Might Also Like:
  • Clinical Rheumatology Year in Review—2022
  • Pediatric Rheumatology Year in Review, 2021: Basic Science
  • A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
  • FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)